Home/Pipeline/Xolatryp

Xolatryp

Cardioprotection (STEMI) and Neuroprotection (stroke, TBI)

Phase 1Active

Key Facts

Indication
Cardioprotection (STEMI) and Neuroprotection (stroke, TBI)
Phase
Phase 1
Status
Active
Company

About Nyrada

Australian‑listed biotech advancing TRPC‑channel inhibitors for cardiovascular and neurological unmet needs.

View full company profile